Medscape1h
Two Oral TYK2 Inhibitors Enter Phase 3 Trials for Plaque Psoriasis on Basis of Phase 2 Promise
Two phase 2 trials with different selective TYK2 inhibitors produce high rates of efficacy in moderate to severe plaque ...